Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Mesalazine Formulation in Active Mild to Moderate Ulcerative Colitis
NCT06176560Phase 3Not yet recruiting
- Sponsor
- Faes Farma
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Salcrozine in ulcerative colitis (UC), sponsored by Faes Farma. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06176560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176560.